Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3) | NCT04260620

Studies
Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)

NCT04260620

Sponsor

Delphinus Medical Technologies, Inc.

Status

Completed

Last Update Posted

Feb 3, 2021Actual

Enrollment

32Actual

Phase

Not provided

Conditions

Breast Cancer Detection
Dense Breast Parenchyma
Benign Breast Findings
Normal Breast Screening
Abnormal Breast Screening

Interventions

Reading of Automated Breast Ultrasound in conjunction with Screening Mammography

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Feb 2021

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 8, 2020Actual

Primary Completion Date

Mar 3, 2020Actual

Completion Date

Mar 3, 2020Actual

First Submitted Date

Feb 5, 2020

First Submission Date that Met QC Criteria

Feb 6, 2020

First Posted Date

Feb 7, 2020Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Feb 1, 2021

Last Update Posted Date

Feb 3, 2021Actual

Name	Class
University of Chicago	OTHER
Boston Biomedical Associates	OTHER

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Yes

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Yes

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in women with dense breast parenchyma.

This reader study will include up to 32 radiologist readers and a sample of 140 breast screening cases that were selected from the library of images collected under Delphinus Protocol #DMT-2015.001 (NCT03257839) Arm 1 Phase B. The reader study image case set will be enriched with cancer cases.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

32Actual

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography	Device	Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.		Digital Screening Mammography with Adjunctive SoftVue Screening Whole Breast Ultrasound

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
MRMC Analysis: ROC AUC	Area under the ROC curve (AUC)	8 Weeks

Secondary Outcomes

Measure	Description	Time Frame
Sensitivity and Specificity	True Positive Rate and True Negative Rate	8 Weeks

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Radiologists of any age, sex, race, ethnicity, or institutional affiliation may participate as study readers. All readers must meet the following base Inclusion Criteria:

Hold a current United States medical license
Be American Board of Radiology Certified
Be MQSA-qualified
Be experienced in reading DM images on a monitor
Be experienced in reading Breast Ultrasound images on a monitor
Have completed a Financial Disclosure showing no Conflicts of Interest
Have provided a current curriculum vitae (CV)
Have provided a signed Readers' Agreement
Have provided written Informed Consent

All qualified and confirmed readers will complete a multi-module SoftVue™ training program prior to their participation in a reading session for this study.

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Readers will evaluate mammography and SoftVue images acquired at study entry from consented participants in protocol DMT-2015.001, and subsequently categorized into the following case types, in random order:

Cancer cases, confirmed by breast biopsy with at least one lesion determined to be malignant during participation
Non-Cancer cases including, but not limited to benign cases, confirmed by breast biopsy with no lesions determined to be malignant, or normal/negative screening or diagnostic imaging during participation

Sampling Method

Probability Sample

Name	Affiliation	Role
Yulei Jiang, Ph.D	University of Chicago	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Delphinus Medical Technologies, Inc.		Novi	Michigan	48374	United States

IPD Sharing Statement Module

Plan to Share IPD

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

ID	Term
D009371	Neoplasms by Site
D009369	Neoplasms
D001941	Breast Diseases
D012871	Skin Diseases